会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Substituted camptothecin derivatives and process for their preparation
    • US5856333A
    • 1999-01-05
    • US776192
    • 1997-01-27
    • Walter CabriIlaria CandianiAngelo BedeschiFranco ZariniSergio Penco
    • Walter CabriIlaria CandianiAngelo BedeschiFranco ZariniSergio Penco
    • A61K31/435A61P35/00C07D491/22
    • C07D491/22
    • The present invention relates to substituted camptothecin derivatives of formula (I) wherein the symbol - - - - represents a single or double bond; R.sub.1, R.sub.2 and R.sub.3 are as defined under (a) or (b) below: (a) R.sub.1 and R.sub.2 are, each independently, hydrogen; C.sub.1 -C.sub.4 alkyl; C.sub.3 -C.sub.7 cycloalkyl; phenyl C.sub.1 -C.sub.6 alkyl; an optionally substituted phenyl ring; --NR.sub.5 R.sub.6 wherein one of R.sub.5 and R.sub.6 is hydrogen, C.sub.1 -C.sub.6 alkyl or benzyl and the other is hydrogen, C.sub.1 -C.sub.6 alkanoyl, an optionally substituted C.sub.1 -C.sub.6 alkoxycarbonyl, an optionally substituted benzoyl, phenyl C.sub.1 -C.sub.6 alkanoyl, an optionally substituted C.sub.1 -C.sub.6 alkoxycarbonyl, an optionally substituted phenoxycarbonyl or phenyl C.sub.1 -C.sub.6 alkoxycarbonyl, or R.sub.5 and R.sub.6, combined together with the nitrogen atom to which they are linked, form a 4-7 membered saturated, optionally substituted, heteromonocyclic ring residue; COOR.sub.8 wherein R.sub.8 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl or phenyl C.sub.1 -C.sub.6 alkyl; or COR.sub.9 wherein Rg is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, phenyl C.sub.1 -C.sub.6 alkyl, an optionally substituted phenyl ring or NR.sub.10 R.sub.11 wherein R.sub.10 and R.sub.11 are, each independently, hydrogen or C.sub.1 -C.sub.6 alkyl; and R.sub.3 is hydrogen, C.sub.1 -C.sub.6 alkyl or an optionally substituted phenyl ring; or (b) R.sub.1 and R.sub.3, combined together, form a 5-8 membered, optionally substituted, carbomonocyclic ring, and R.sub.2 is hydrogen, C.sub.1 -C.sub.4 alkyl or C.sub.3 -C.sub.7 cycloalkyl; R.sub.4 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl or phenyl C.sub.1 -C.sub.6 alkyl; X is hydrogen,C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.3 -C.sub.7 cycloalkoxy, C.sub.1 -C.sub.6 alkanoyloxy, benzoyloxy, amino, hydroxy, nitro, halogen or it is a methylenedioxy group linked to the positions 10 and 11 of the molecule, and the pharmaceutically acceptable salts thereof. The compounds according to the invention are useful in therapy as antitumor agents. ##STR1##
    • 7. 发明授权
    • Process for the preparation of 9-amino camptothecin
    • 制备9-氨基喜树碱的方法
    • US06403603B1
    • 2002-06-11
    • US08284129
    • 1994-08-02
    • Angelo BedeschiWalter CabriIlaria CandianiFranco Zarini
    • Angelo BedeschiWalter CabriIlaria CandianiFranco Zarini
    • C07D49122
    • C07D491/22
    • 9-Amino-20(S)-camptothecin (I) is prepared by reducing 12-nitro-20(S)-camptothecin (II); converting the resulting 12-amino-20(S)-camptothecin (III) into a compound of formula (IV) wherein X is a group which can be reductively removed; reacting the compound of formula (IV) with a nitrating agent, to obtain thereby the corresponding 9-nitro-20(S)-camptothecin compound of formula (V) substituted at the 12-position by the group X; reducing in a single step the compound of formula (V), so obtaining the 9-amino-20(S)-camptothecin of formula (I); or reducing the compound of formula (V), so obtaining the corresponding 9-amino-20(S)-camptothecin compound of formula (VI) substituted at the 12-position by the group X and reductively removing the X group from the compound of formula (VI), so obtaining 9-amino-20(S)-camptothecin.
    • 通过还原12-硝基-20(S) - 喜树碱(II)制备9-氨基-20(S) - 喜树碱(I) 将所得的12-氨基-20(S) - 喜树碱(III)转化成式(IV)的化合物,其中X是可被还原去除的基团; 使式(Ⅳ)化合物与硝化剂反应,由此获得在X-12位被12位取代的相应的9-硝基-20(S)喜树碱化合物。 在一步中还原式(Ⅴ)化合物,从而得到式(I)的9-氨基-20(S) - 喜树碱; 或降低式(Ⅴ)化合物,从而得到在X基上被12位取代的相应的式(Ⅵ)的9-氨基-20(S) - 喜树碱化合物,并将X基团从 式(VI),因此得到9-氨基-20(S) - 喜树碱。
    • 9. 发明授权
    • Method for the preparation of 9-amino camptothecin
    • 9-氨基喜树碱的制备方法
    • US5840899A
    • 1998-11-24
    • US602792
    • 1996-09-30
    • Angelo BedeschiWalter CabriIlaria CandianiFranco Zarini
    • Angelo BedeschiWalter CabriIlaria CandianiFranco Zarini
    • C07D491/22
    • C07D491/22
    • 9-Amino camptothecin of formula (I) ##STR1## is prepared by: 1) reducing a compound of formula (II): ##STR2## wherein Hal is 10- or 12-halogen, in a single step to the 9-amino-camptothecin of formula (I) or, alternatively, 2a) reductively removing the Hal group from a compound of formula (II) so obtaining the compound of formula (III): ##STR3## and 2b) reducing the compound of formula (III) so obtaining the 9-amino camptothecin of formula (I); the said steps 1 and 2a) and, optionally, step 2b) each being carried out in the presence of a catalytic amount of a compound of formula PdL.sub.2 wherein L is acetate or halogen and, additionally, in the presence of an ammonium formate as a hydrogen source. The 9-amino camptothecin of formula (I) is useful as inhibitor of the enzyme topoisomerase I. It is useful in the treatment of cancers, in particular leukaemia, colon and rectal tumours.
    • PCT No.PCT / EP95 / 01692 Sec。 371日期1996年9月30日 102(e)1996年9月30日PCT PCT 1995年5月4日PCT公布。 公开号WO95 / 32207 PCT (I)的氨基喜树碱的制备通过以下方法制备:1)还原式(II)的化合物:其中Hal是10-或12-卤素 (I)的9-氨基喜树碱的单步骤,或者替代地,2a)从式(II)化合物还原性除去Hal基团,从而得到式(III)的化合物: III)和2b)还原式(III)的化合物,从而获得式(I)的9-氨基喜树碱; 所述步骤1和2a)和任选的步骤2b)各自在催化量的式PdL 2化合物的存在下进行,其中L是乙酸酯或卤素,另外在甲酸铵存在下,作为 氢源。 式(I)的9-氨基喜树碱可用作拓扑异构酶I的抑制剂。它可用于治疗癌症,特别是白血病,结肠和直肠肿瘤。